One size doesn't fit all, when using hormone therapy to treat endometriosis

Endometriosis—a condition caused by uterine tissue growing outside of the organ—affects 10% of reproductive-aged women, whom it causes chronic pain that is significant and debilitating. The standard first-line treatment for all women with endometriosis is hormonal, specifically progestin-based, therapy.

Yet a team of researchers at Yale has shown that the effectiveness of progestin-therapy depends on whether a woman's endometriotic have the progesterone receptor (PR) present. This study appears online in the Journal of Clinical Endocrinology & Metabolism.

The researchers tested the endometriotic lesions of 52 women who had undergone surgical evaluation for endometriosis at Yale New Haven Hospital for their PR . They found a significant association between PR status and responsiveness to progestin-therapy. Those whose endometriotic lesions were PR-positive responded much better to the progestin-therapy, while those whose lesions were PR-negative found little relief from progestin-therapy alone.

From these findings, the research team concluded that knowing a woman's PR-status may help them develop a "novel, targeted, precision-based" approach to treating and managing endometriosis individually. "Receptor status in endometriosis could be used in a manner analogous to the use of estrogen/progesterone receptor status in breast cancer for tailoring hormonal-based regimens," said Dr. Valerie Flores, first author and clinical instructor at the Yale School of Medicine.

"Such an approach to management would make trialing progestin-based therapy to determine response unnecessary," said Flores, "and would therefore minimize delays in providing the optimal medical therapy for each individual patient."


Explore further

Biomarkers can predict whether women with endometriosis will respond to the first-line treatment

More information: Valerie A Flores et al, Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis, The Journal of Clinical Endocrinology & Metabolism (2018). DOI: 10.1210/jc.2018-01227
Provided by Yale University
Citation: One size doesn't fit all, when using hormone therapy to treat endometriosis (2018, October 25) retrieved 20 September 2019 from https://medicalxpress.com/news/2018-10-size-doesnt-hormone-therapy-endometriosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more